Gustave Roussy, Cancer Campus, Grand Paris

🇫🇷France
Ownership
Private
Employees
-
Market Cap
-
Website

A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors

First Posted Date
2014-04-15
Last Posted Date
2016-06-09
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
34
Registration Number
NCT02115165
Locations
🇫🇷

Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France

Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment

First Posted Date
2014-04-07
Last Posted Date
2016-06-10
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
2200
Registration Number
NCT02105168
Locations
🇫🇷

Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France

Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma

First Posted Date
2014-03-21
Last Posted Date
2016-06-09
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
4
Registration Number
NCT02094391
Locations
🇫🇷

Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France

Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer

First Posted Date
2014-03-17
Last Posted Date
2024-08-15
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
280
Registration Number
NCT02089100
Locations
🇫🇷

Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val De Marne, France

Measurement of Cardiac Index Using an Implanted Central Venous Access Port in Patients Scheduled for Oncologic High-risk Surgery

Completed
Conditions
First Posted Date
2014-02-14
Last Posted Date
2014-02-14
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
33
Registration Number
NCT02063009
Locations
🇫🇷

Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France

Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer

First Posted Date
2014-01-24
Last Posted Date
2017-08-08
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
195
Registration Number
NCT02044354
Locations
🇫🇷

Gustave Roussy, Villejuif, Val de Marne, France

Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients

First Posted Date
2014-01-20
Last Posted Date
2016-06-09
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
27
Registration Number
NCT02040064
Locations
🇫🇷

Gustave Roussy, Villejuif, Val de Marne, France

Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma

First Posted Date
2014-01-01
Last Posted Date
2024-05-24
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
29
Registration Number
NCT02025881
Locations
🇫🇷

Centre Léon Bérard, Lyon, France

🇫🇷

Gustave Roussy, Villejuif, Val De Marne, France

🇫🇷

Centre Oscar Lambret, Lille, France

and more 10 locations

A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With Gemcitabine

First Posted Date
2013-12-23
Last Posted Date
2016-07-12
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
52
Registration Number
NCT02018874
Locations
🇫🇷

Gustave Roussy, Villejuif, Val de Marne, France

Randomized Phase II Study to Assess PD 0332991 in Breast Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2013-12-11
Last Posted Date
2016-06-09
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
132
Registration Number
NCT02008734
Locations
🇫🇷

Gustave Roussy, Villejuif, Val de Marne, France

© Copyright 2024. All Rights Reserved by MedPath